Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2017-04-26
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, randomized, 3-arm trial investigating the efficacy of two
Sym004 doses (Arm A and Arm B) compared with a control group (Arm C) in subjects with
metastatic colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor
receptor (EGFR) monoclonal antibodies (mAbs).